On January 12, 2026, Dogwood Therapeutics, Inc. announced a financing of up to $26.8 million that will fund the company through the Phase 2b data readout in the third quarter of 2026. The company received approximately $12.5 million in gross proceeds from the sale of 4,386,037 shares of common stock (or pre-funded warrants) together with warrants to purchase up to an aggregate of 4,386,037 shares of common stock at a combined purchase price of $2.85. The warrants have an exercise price of $3.28 per share, are exercisable upon shareholder approval, and will expire five and one-half years from the effective data of shareholder approval. If exercised in full, the warrants could bring in an additional $14.4 million in gross proceeds.
